Parkview Research Center

Running trials

• Recruiting

  A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

  NCT07023627· Phase 2· Source

• Recruiting

  A Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer in Adjuvant Setting

  NCT07022483· Phase 3· Source

• Recruiting

  OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events

  NCT07136012· Phase 3· Source

• Recruiting

  Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer

  NCT06801834· Phase 3· Source

• Recruiting

  Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer

  NCT05803941· Phase 4· Source

• Recruiting

  Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer

  NCT05797831· Phase 2/3· Source

• Active, not recruiting

  A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

  NCT05702034· Phase 3· Source

• Active, not recruiting

  RADIANCE Continued Access Protocol

  NCT05017935· Source

• Active, not recruiting

  An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

  NCT04720157· Phase 3· Source

• Recruiting

  Staged Complete Revascularization for Coronary Artery Disease vs Medical Management Alone in Patients With AS Undergoing Transcatheter Aortic Valve Replacement

  NCT04634240· Source

• Active, not recruiting

  Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

  NCT04498117· Phase 3· Source

• Recruiting

  Integrated Cancer Repository for Cancer Research

  NCT02012699· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Endometrial cancer3 recruiting
• Coronary artery disease2 recruiting
• Lung cancer2 recruiting
• Ovarian cancer2 recruiting
• Prostate cancer2 recruiting
• Bladder cancer1 recruiting
• Colorectal cancer1 recruiting
• Gastric and esophageal cancer1 recruiting
• Head and neck cancer1 recruiting
• Kidney cancer1 recruiting
• Liver and biliary tract cancer1 recruiting
• Melanoma1 recruiting
• Mesothelioma1 recruiting
• Multiple myeloma1 recruiting
• Neuroendocrine tumours1 recruiting
• Pancreatic cancer1 recruiting
• Sarcoma1 recruiting
• Thyroid cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Terminated

  Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia

  NCT05079230· Phase 3· Source

• Terminated

  EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer

  NCT04892472· Phase 2· Source

• Completed

  Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer

  NCT03511664· Phase 3· Source

• Completed

  Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO]

  NCT03555422· Phase 3· Source

• Completed

  Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma

  NCT02807636· Phase 3· Source